{"organizations": [], "uuid": "7a38afe708b1acb261c41ab5f1ee4ff3b2a4e11e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cerus-chronic-anemia-phase-3-study/brief-cerus-chronic-anemia-phase-3-study-met-primary-efficacy-and-safety-endpoints-idUSFWN1PI18D", "country": "US", "domain_rank": 408, "title": "BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T23:21:00.000+02:00", "replies_count": 0, "uuid": "7a38afe708b1acb261c41ab5f1ee4ff3b2a4e11e"}, "author": "", "url": "https://www.reuters.com/article/brief-cerus-chronic-anemia-phase-3-study/brief-cerus-chronic-anemia-phase-3-study-met-primary-efficacy-and-safety-endpoints-idUSFWN1PI18D", "ord_in_thread": 0, "title": "BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "safety endpoints reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "cerus corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "cerus corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 22 PM / Updated 12 minutes ago BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints Reuters Staff 1 Min Read \nJan 23 (Reuters) - Cerus Corp: \n* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS \n* CERUS CORP - STUDY SUCCESSFULLY MET PRIMARY EFFICACY AND SAFETY ENDPOINTS \n* CERUS CORP - FULL RESULTS OF STUDY ARE PLANNED FOR SUBMISSION AND PRESENTATION AT UPCOMING SCIENTIFIC CONFERENCES AND FOR PUBLICATION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-23T23:21:00.000+02:00", "crawled": "2018-01-23T23:39:48.027+02:00", "highlightTitle": ""}